X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs NOVARTIS - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA NOVARTIS GLENMARK PHARMA/
NOVARTIS
 
P/E (TTM) x 23.1 302.8 7.6% View Chart
P/BV x 3.2 33.6 9.4% View Chart
Dividend Yield % 0.3 1.4 24.5%  

Financials

 GLENMARK PHARMA   NOVARTIS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
NOVARTIS
Mar-18
GLENMARK PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs930758 122.7%   
Low Rs517579 89.4%   
Sales per share (Unadj.) Rs322.6228.4 141.3%  
Earnings per share (Unadj.) Rs28.531.7 89.8%  
Cash flow per share (Unadj.) Rs39.232.8 119.6%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.31.5 18.5%  
Book value per share (Unadj.) Rs183.0297.1 61.6%  
Shares outstanding (eoy) m282.1724.69 1,142.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.9 76.6%   
Avg P/E ratio x25.421.1 120.6%  
P/CF ratio (eoy) x18.520.4 90.5%  
Price / Book Value ratio x4.02.2 175.8%  
Dividend payout %7.031.5 22.3%   
Avg Mkt Cap Rs m204,20616,505 1,237.2%   
No. of employees `00013.70.7 2,053.3%   
Total wages/salary Rs m18,7181,445 1,295.1%   
Avg. sales/employee Rs Th6,636.88,441.3 78.6%   
Avg. wages/employee Rs Th1,364.72,163.6 63.1%   
Avg. net profit/employee Rs Th586.11,173.1 50.0%   
INCOME DATA
Net Sales Rs m91,0315,639 1,614.4%  
Other income Rs m9141,718 53.2%   
Total revenues Rs m91,9457,357 1,249.7%   
Gross profit Rs m16,154-63 -25,846.1%  
Depreciation Rs m3,01925 11,932.0%   
Interest Rs m2,85655 5,164.0%   
Profit before tax Rs m11,1931,575 710.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155792 398.5%   
Profit after tax Rs m8,039784 1,025.9%  
Gross profit margin %17.7-1.1 -1,601.0%  
Effective tax rate %28.250.3 56.1%   
Net profit margin %8.813.9 63.5%  
BALANCE SHEET DATA
Current assets Rs m69,8879,522 734.0%   
Current liabilities Rs m32,8793,296 997.5%   
Net working cap to sales %40.7110.4 36.8%  
Current ratio x2.12.9 73.6%  
Inventory Days Days8137 222.4%  
Debtors Days Days9328 328.9%  
Net fixed assets Rs m28,89246 62,807.6%   
Share capital Rs m282123 228.7%   
"Free" reserves Rs m51,3537,213 711.9%   
Net worth Rs m51,6357,336 703.8%   
Long term debt Rs m41,4180-   
Total assets Rs m125,95411,105 1,134.2%  
Interest coverage x4.929.5 16.7%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.70.5 142.3%   
Return on assets %8.67.6 114.5%  
Return on equity %15.610.7 145.8%  
Return on capital %15.122.2 67.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31761 59,929.2%   
Fx outflow Rs m9,7203,630 267.7%   
Net fx Rs m26,598-3,570 -745.1%   
CASH FLOW
From Operations Rs m16,4811,610 1,023.7%  
From Investments Rs m-10,133687 -1,475.0%  
From Financial Activity Rs m-4,685-2,677 175.0%  
Net Cashflow Rs m1,770-380 -466.3%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 2.0 345.0%  
FIIs % 34.4 1.6 2,150.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.5 48.8%  
Shareholders   56,727 41,647 136.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   WOCKHARDT LTD.  FULFORD INDIA  MERCK LTD  BIOCON LTD  UNICHEM LAB  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of the Sell-Off in Share Markets, September Quarter Results, and Top Cues in Focus Today(Pre-Open)

On Wednesday, share markets in India traded on a volatile note throughout the day and witnessed selling pressure during the closing hours and ended deep in red.

Related Views on News

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

My Top 3 Tips to Navigate the Market Crash(The 5 Minute Wrapup)

Oct 8, 2018

Steep corrections are never easy to handle. It's hard to watch the value of your shares drop so much. But you can take steps to make the most of it.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)

Oct 12, 2018

Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.

ICICI Prudential Manufacture In India Fund: A Make In India Prodigy, Should You Invest?(Outside View)

Oct 8, 2018

PersonalFN briefly explains if you should be investing in the NFO: ICICI Prudenetial Manufacture in India Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 17, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS